Pharvaris (PHVS) Expected to Announce Earnings on Tuesday

Key Points

• Pharvaris will report quarterly earnings before the market opens on Tuesday, May 12, with analysts expecting about ($0.8267) EPS
• The stock trades near its 1-year high with a market cap of about $1.98 billion and a consensus analyst rating of “Moderate Buy” with a $42.73 average price target.
• Insiders have been net sellers recently, disposing of a total of 150,659 shares worth $4.49 million over the last 90 days (including sales by Anne Lesage and Peng Lu).

Pharvaris (NASDAQ:PHVS - Get Free Report) is expected to post its results before the market opens on Tuesday, May 12th. Analysts expect Pharvaris to post earnings of ($0.8267) per share for the quarter.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Stock Performance

Shares of PHVS traded up $0.22 during mid-day trading on Tuesday, hitting $30.24. 96,907 shares of the company were exchanged, compared to its average volume of 197,820. Pharvaris has a 1-year low of $14.59 and a 1-year high of $31.14. The company has a 50 day moving average of $27.62 and a 200-day moving average of $26.09. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -8.97 and a beta of -2.34.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Royal Bank Of Canada reduced their price target on shares of Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research report on Monday, April 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wedbush upped their price target on shares of Pharvaris from $41.00 to $42.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 7th. Wolfe Research assumed coverage on shares of Pharvaris in a research note on Thursday, April 9th. They set an "outperform" rating and a $42.00 price objective for the company. Finally, Wall Street Zen cut shares of Pharvaris from a "sell" rating to a "strong sell" rating in a research note on Monday, April 13th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $42.73.

Insider Activity

In other news, insider Anne Lesage sold 19,200 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total value of $580,992.00. Following the completion of the sale, the insider owned 133,969 shares of the company's stock, valued at $4,053,901.94. This represents a 12.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Peng Lu sold 15,000 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the completion of the sale, the insider directly owned 66,083 shares of the company's stock, valued at approximately $1,998,349.92. This trade represents a 18.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 150,659 shares of company stock valued at $4,489,587 in the last 90 days.

Institutional Trading of Pharvaris

Hedge funds have recently made changes to their positions in the company. Barclays PLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at approximately $77,000. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after purchasing an additional 783 shares during the period. Public Employees Retirement System of Ohio boosted its position in shares of Pharvaris by 39.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company's stock worth $156,000 after purchasing an additional 1,769 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its position in shares of Pharvaris by 50.1% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 8,239 shares of the company's stock worth $229,000 after purchasing an additional 2,750 shares during the period. Finally, Alliancebernstein L.P. purchased a new position in shares of Pharvaris during the 3rd quarter worth approximately $224,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.